REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 225.05 Billion KRW | 7.06% |
| 2022 | 210.2 Billion KRW | 1.39% |
| 2021 | 207.31 Billion KRW | 248.81% |
| 2020 | 59.43 Billion KRW | 76.6% |
| 2019 | 33.65 Billion KRW | -4.57% |
| 2018 | 35.26 Billion KRW | 3.61% |
| 2017 | 34.03 Billion KRW | 1602.0% |
| 2016 | 2 Billion KRW | 0.0% |
| 2015 | 2 Billion KRW | -86.5% |
| 2014 | 14.81 Billion KRW | -28.65% |
| 2013 | 20.75 Billion KRW | 59.26% |
| 2012 | 13.03 Billion KRW | 13.44% |
| 2011 | 11.49 Billion KRW | 165.46% |
| 2010 | 4.32 Billion KRW | -34.98% |
| 2009 | 6.65 Billion KRW | -19.8% |
| 2008 | 8.3 Billion KRW | -7.17% |
| 2007 | 8.94 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 225.11 Billion KRW | 0.03% |
| 2024 Q2 | 223.17 Billion KRW | -0.86% |
| 2023 Q1 | 210.23 Billion KRW | 0.02% |
| 2023 FY | 225.05 Billion KRW | 7.06% |
| 2023 Q3 | 224.92 Billion KRW | -0.25% |
| 2023 Q4 | 225.05 Billion KRW | 0.06% |
| 2023 Q2 | 225.49 Billion KRW | 7.26% |
| 2022 Q4 | 210.2 Billion KRW | 1.36% |
| 2022 Q3 | 207.38 Billion KRW | 0.12% |
| 2022 FY | 210.2 Billion KRW | 1.39% |
| 2022 Q1 | 207.23 Billion KRW | -0.04% |
| 2022 Q2 | 207.14 Billion KRW | -0.05% |
| 2021 Q3 | 207.39 Billion KRW | 48.24% |
| 2021 Q2 | 139.9 Billion KRW | 61.2% |
| 2021 FY | 207.31 Billion KRW | 248.81% |
| 2021 Q1 | 86.79 Billion KRW | 46.03% |
| 2021 Q4 | 207.31 Billion KRW | -0.04% |
| 2020 FY | 59.43 Billion KRW | 76.6% |
| 2020 Q1 | 41.33 Billion KRW | 22.83% |
| 2020 Q2 | 48.27 Billion KRW | 16.78% |
| 2020 Q3 | 53.2 Billion KRW | 10.2% |
| 2020 Q4 | 59.43 Billion KRW | 11.72% |
| 2019 Q2 | 37.95 Billion KRW | 6.67% |
| 2019 Q3 | 22.29 Billion KRW | -41.24% |
| 2019 FY | 33.65 Billion KRW | -4.57% |
| 2019 Q4 | 33.65 Billion KRW | 50.93% |
| 2019 Q1 | 35.57 Billion KRW | 0.88% |
| 2018 Q2 | 34.63 Billion KRW | 0.88% |
| 2018 Q1 | 34.33 Billion KRW | 0.88% |
| 2018 Q4 | 35.26 Billion KRW | 1.1% |
| 2018 FY | 35.26 Billion KRW | 3.61% |
| 2018 Q3 | 34.88 Billion KRW | 0.7% |
| 2017 Q3 | 36.97 Billion KRW | 0.0% |
| 2017 FY | 34.03 Billion KRW | 1602.0% |
| 2017 Q4 | 34.03 Billion KRW | -7.94% |
| 2017 Q1 | - KRW | -100.0% |
| 2016 Q4 | 2 Billion KRW | 0.0% |
| 2016 Q2 | 2 Billion KRW | 0.0% |
| 2016 FY | 2 Billion KRW | 0.0% |
| 2016 Q1 | 2 Billion KRW | 0.0% |
| 2015 Q4 | 2 Billion KRW | -60.0% |
| 2015 FY | 2 Billion KRW | -86.5% |
| 2015 Q3 | 5 Billion KRW | -30.45% |
| 2015 Q2 | 7.18 Billion KRW | -34.59% |
| 2015 Q1 | 10.98 Billion KRW | -25.8% |
| 2014 Q4 | 14.81 Billion KRW | -21.1% |
| 2014 Q3 | 18.77 Billion KRW | 1.93% |
| 2014 Q1 | 15.84 Billion KRW | -23.69% |
| 2014 Q2 | 18.41 Billion KRW | 16.28% |
| 2014 FY | 14.81 Billion KRW | -28.65% |
| 2013 Q1 | 13.03 Billion KRW | 0.04% |
| 2013 Q3 | 20.07 Billion KRW | -2.45% |
| 2013 Q4 | 20.75 Billion KRW | 3.38% |
| 2013 Q2 | 20.58 Billion KRW | 57.86% |
| 2013 FY | 20.75 Billion KRW | 59.26% |
| 2012 Q1 | 7.78 Billion KRW | -32.27% |
| 2012 Q3 | 4.89 Billion KRW | -34.15% |
| 2012 Q4 | 13.03 Billion KRW | 166.22% |
| 2012 FY | 13.03 Billion KRW | 13.44% |
| 2012 Q2 | 7.43 Billion KRW | -4.47% |
| 2011 Q2 | 14.7 Billion KRW | -10.77% |
| 2011 Q1 | 16.47 Billion KRW | 280.65% |
| 2011 Q3 | 15.43 Billion KRW | 4.99% |
| 2011 Q4 | 11.49 Billion KRW | -25.55% |
| 2011 FY | 11.49 Billion KRW | 165.46% |
| 2010 Q3 | 4.51 Billion KRW | -13.41% |
| 2010 FY | 4.32 Billion KRW | -34.98% |
| 2010 Q4 | 4.32 Billion KRW | -4.13% |
| 2010 Q2 | 5.21 Billion KRW | 0.0% |
| 2009 FY | 6.65 Billion KRW | -19.8% |
| 2008 FY | 8.3 Billion KRW | -7.17% |
| 2007 FY | 8.94 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -366.381% |
| Yuhan Corporation | 230.07 Billion KRW | 2.181% |
| Yuhan Corporation | 230.07 Billion KRW | 2.181% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -471.099% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -471.099% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -471.099% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 41.095% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -27.959% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 67.472% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -32.167% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -32.167% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -32.167% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -37693.302% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 51.915% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -420.081% |
| HANDOK Inc. | 300.01 Billion KRW | 24.985% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -30.066% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -633.98% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -183.49% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -24.341% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -94410.355% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -54.094% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -236.493% |
| Boryung Corporation | 204.21 Billion KRW | -10.204% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -474.045% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -89.697% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -164.272% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -164.272% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 51.897% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 4.493% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -17338.865% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -35508.329% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -148.727% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -387.642% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -387.642% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -457.906% |
| CKD Bio Corp. | 146.92 Billion KRW | -53.174% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 52.084% |
| JW Holdings Corporation | 554.58 Billion KRW | 59.42% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 60.715% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 44.664% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | -2.407% |
| JW Lifescience Corporation | 46.31 Billion KRW | -385.943% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | -3.311% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -164.876% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -748.201% |